etwas leben in die pommesbude ++++++++++
Anzeige
Meldung des Tages: Doppelter Hebel: 2026 – das Jahr für diesen Med-Tech SmallCap!
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 10 11 12 14 15 16 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 10 11 12 14 15 16 ...
Response Biomedical - Zukunftswert
Beiträge:
1.009
Zugriffe: 132.422 / Heute: 69
Zugriffe: 132.422 / Heute: 69
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
so deine 12 cent sind an allen Börsenplätzen erreicht, dann hoffen wir mal, dass wir uns drüber festsetzen
Berlin 22.10.2009, 12:30:40 0,120 EUR 22,45% 14.000 0,085 0,120 15.000
Frankfurt 22.10.2009, 13:06:48 0,120 EUR 41,18% 30.000 0,115 0,122 30.000
Stuttgart 22.10.2009, 12:57:30 0,120 EUR 42,86% 35.000 0,115 0,123 35.000
Berlin 22.10.2009, 12:30:40 0,120 EUR 22,45% 14.000 0,085 0,120 15.000
Frankfurt 22.10.2009, 13:06:48 0,120 EUR 41,18% 30.000 0,115 0,122 30.000
Stuttgart 22.10.2009, 12:57:30 0,120 EUR 42,86% 35.000 0,115 0,123 35.000
...das ist einfach klasse.
Ich hab mit 25 % gerechnet aber nicht mit 40% am heutigen Tag.
Hmmm.. wenn die Meldung heute um 10:30 bei uns veröffentlich wurde.
Wann war sie dann in kanada bekannt? 4:30 in der Früh?
Das die Meldung in Kanada Nachbörslich kam dürfte sicher sein.... daher wirds gleich nochmal aufwärts gehen.
Ich hab mit 25 % gerechnet aber nicht mit 40% am heutigen Tag.
Hmmm.. wenn die Meldung heute um 10:30 bei uns veröffentlich wurde.
Wann war sie dann in kanada bekannt? 4:30 in der Früh?
Das die Meldung in Kanada Nachbörslich kam dürfte sicher sein.... daher wirds gleich nochmal aufwärts gehen.
v^v^v^ ...nur ein Spekulant ©
lassen wir die Jungs drüben erstmal wach werden...dann zünden wir hoffentlich Stufe 2 für heute;-)
Denke, dass in den USA heute auch fleißig gehandelt wird und nicht nur bei uns und in Kanada
Denke, dass in den USA heute auch fleißig gehandelt wird und nicht nur bei uns und in Kanada
seit ca 2 monaten ++++ werde dieses jahr keine einzige aktie verkaufen egal wie der kurs sich entwickelt ++++ habe ich mir zumindest mal vorgenommen ++++
Response Biomedical Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to the RAMP(R) Influenza A/B Assay Package Insert
7:30 AM ET, October 22, 2009
VANCOUVER, British Columbia, Oct 22, 2009 (BUSINESS WIRE) -- Response Biomedical Corporation (RBM)(US:RPBI.F) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company's RAMP(R) Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP(R) Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M(TM) Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.
Although the RAMP(R) Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP(R) Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
"We are very cognizant of physicians' needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic," said S. Wayne Kay, Chief Executive Officer. "This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3M(TM) Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.
Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.
Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.
SOURCE: Response Biomedical Corporation
Response Biomedical Corporation
Bill Wickson, 604-456-6073
Director, Investor Relations
bwickson@responsebio.com
cxa.marketwatch.com/TSX/en/Market/...50C680BE9A7}&symb=RBM
7:30 AM ET, October 22, 2009
VANCOUVER, British Columbia, Oct 22, 2009 (BUSINESS WIRE) -- Response Biomedical Corporation (RBM)(US:RPBI.F) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company's RAMP(R) Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP(R) Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M(TM) Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.
Although the RAMP(R) Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP(R) Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
"We are very cognizant of physicians' needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic," said S. Wayne Kay, Chief Executive Officer. "This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3M(TM) Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.
Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.
Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.
SOURCE: Response Biomedical Corporation
Response Biomedical Corporation
Bill Wickson, 604-456-6073
Director, Investor Relations
bwickson@responsebio.com
cxa.marketwatch.com/TSX/en/Market/...50C680BE9A7}&symb=RBM
totaler Schwachsinn jetzt rauszugehen... um 15:30 gehts nochmal hoch.
Response wird ja wohl nicht schwächeln... in den nächsten Tagen wird die heutige Neuigkeit eh nochmal von irgendwelchen Analysten kommentiert und mit einem Kursziel über 20 Cent geworben.
Response wird ja wohl nicht schwächeln... in den nächsten Tagen wird die heutige Neuigkeit eh nochmal von irgendwelchen Analysten kommentiert und mit einem Kursziel über 20 Cent geworben.
v^v^v^ ...nur ein Spekulant ©
ja, ich bin - das muss ich fairerweise sagen - rausgegangen. ich hab das zu oft durch, dass man schön im plus steht und die canadiens, bzw. us-boys cremen dann erst mal richtig ab. mein einstiegskurs war mit 9.6 cent auch nicht gar so billig. falls die lucy noch mal aufs parkett geht, dann kauf ich mich noch mal ein.
und wie sagte einst Oliver Kahn über seine Teamkollegen
"Eier, wir brauchen Eier"
"Eier, wir brauchen Eier"
.. auch ich habe mir manchmal schöne Kurse ausgedacht, eher die Amis oder Kanis mir einen Strich durch die Rechnung gemacht haben.
Jedoch ist etwas zu unterscheiden:
1. es handelt sich hierbei um eine klare Kaufneuigkeit und 2. ist das hier keine Zockeraktie sondern eher ein Langzeitinvest.
Egal wie der Kurs in den nächsten Tagen steht, ob wieder 8 Ct. oder 13... eins ist klar, in einem Jahr oder mehr steht keine Null vor dem Komma.
Jedoch ist etwas zu unterscheiden:
1. es handelt sich hierbei um eine klare Kaufneuigkeit und 2. ist das hier keine Zockeraktie sondern eher ein Langzeitinvest.
Egal wie der Kurs in den nächsten Tagen steht, ob wieder 8 Ct. oder 13... eins ist klar, in einem Jahr oder mehr steht keine Null vor dem Komma.
v^v^v^ ...nur ein Spekulant ©
Frankfurt 22.10.2009, 14:49:39 0,115 EUR 35,29% 30.000 0,113 0,120 20.000
Stuttgart 22.10.2009, 14:50:28 0,113 EUR 34,52% 50.000 0,108 0,118 500.000
Stuttgart 22.10.2009, 14:50:28 0,113 EUR 34,52% 50.000 0,108 0,118 500.000
dachte schon falsch investiert zu sein, habe sie mir gestern eine als letzte behalten und wie ich recht hatte :D))
politik ist die kunst über probleme zu reden, die eigentlich keine (mehr) sind, um die wahren probleme im hintergrund zu lösen
zu österreichisch: unterhalte den stammtisch
zu österreichisch: unterhalte den stammtisch
stehen zum Brifkurs mit ca. 35% im Plus.
Falls ich mich nicht verrechnet habe...
Falls ich mich nicht verrechnet habe...
v^v^v^ ...nur ein Spekulant ©
Der letzte Kurs bei 12 und der Briefkurs bei 16 ...
dann über einen Dreisatz durchrechnen und man erhält +33,3 %..
Nur eine Theorie
dann über einen Dreisatz durchrechnen und man erhält +33,3 %..
Nur eine Theorie
v^v^v^ ...nur ein Spekulant ©
gerade ein nachdenkbier genommen und..
bin zu dem entschluss gekommen
diese aktie zu halten,
bis die erste grippewelle kommt,
dann werd ich schaun, wie die aktie weiter reagiert
bin zu dem entschluss gekommen
diese aktie zu halten,
bis die erste grippewelle kommt,
dann werd ich schaun, wie die aktie weiter reagiert
politik ist die kunst über probleme zu reden, die eigentlich keine (mehr) sind, um die wahren probleme im hintergrund zu lösen
zu österreichisch: unterhalte den stammtisch
zu österreichisch: unterhalte den stammtisch
hast wohl den Kurs von OTC genommen....
in Kanada standen wir gestern bei 0,14....
hier noch ein Realtime Link
de.advfn.com/...pid=qkchart&cb=1256216091&symbol=T^RBM
in Kanada standen wir gestern bei 0,14....
hier noch ein Realtime Link
de.advfn.com/...pid=qkchart&cb=1256216091&symbol=T^RBM
ht
aber die Umsätze stimmen
knappe 1,5 Mille in Kanada und über 100k in den USA
Hol mir jetzt erstmal nen Kaffee und verfolge diesen Tag sehr gelassen
aber die Umsätze stimmen
knappe 1,5 Mille in Kanada und über 100k in den USA
Hol mir jetzt erstmal nen Kaffee und verfolge diesen Tag sehr gelassen
...dennoch ganz ordentlich für den Anfang.
...bei uns hat es ja auch zaghaft begonnen.
...bei uns hat es ja auch zaghaft begonnen.
v^v^v^ ...nur ein Spekulant ©
... mein Gewinn schmilzt dahin.
Abwarten...
Abwarten...
v^v^v^ ...nur ein Spekulant ©
bisher net aus den Startlöchern geholfen, glaube nicht, dass wir heut noch einen größeren Satz nach oben machen.
Ich hab keine Ahnung, warum gute News bzw auch an manchen Tage größere Käufe keine Auswirkung auf den Kurs haben, noch nicht einmal die Q2 Zahlen haben den Kurs großartig interessiert...
Schon vom Verlauf her eine komische Aktie ;-)
Ich hab keine Ahnung, warum gute News bzw auch an manchen Tage größere Käufe keine Auswirkung auf den Kurs haben, noch nicht einmal die Q2 Zahlen haben den Kurs großartig interessiert...
Schon vom Verlauf her eine komische Aktie ;-)
Dilution im Spiel?
Sometimes you gotta roll the hard six.
As at June 30, 2009 there were 254,672,008 common shares issued and outstanding for a total of
$89,084,660 in share capital, 9,882,625 (of which 2,104,546 are exercisable at a weighted-average
exercise price of $0.69 per share) common shares issuable upon the exercise of outstanding stock
options at a weighted-average exercise price of $0.64 per share, 3,040,617 common shares reserved
for future grant or issuance under the Company’s stock option plan and 61,698,334 common shares
issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $0.24
per share.
www.responsebio.com/pdf/2009%20Q2.pdf
bei einem Kurs von sagen wir mal 0,13-0,16$Can sieht das nicht nach Verwässerung aus
$89,084,660 in share capital, 9,882,625 (of which 2,104,546 are exercisable at a weighted-average
exercise price of $0.69 per share) common shares issuable upon the exercise of outstanding stock
options at a weighted-average exercise price of $0.64 per share, 3,040,617 common shares reserved
for future grant or issuance under the Company’s stock option plan and 61,698,334 common shares
issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $0.24
per share.
www.responsebio.com/pdf/2009%20Q2.pdf
bei einem Kurs von sagen wir mal 0,13-0,16$Can sieht das nicht nach Verwässerung aus
finde ich.
H1N1 Flu (Swine Flu) ist das Thema Nr.1 in letzter Zeit, wird wohl auch in nächster Zeit Nr.1 bleiben.
Die Zulassung von der FDA ist wichtig für weitere Signifikante Umsätze in nächster Zeit......
H1N1 Flu (Swine Flu) ist das Thema Nr.1 in letzter Zeit, wird wohl auch in nächster Zeit Nr.1 bleiben.
Die Zulassung von der FDA ist wichtig für weitere Signifikante Umsätze in nächster Zeit......
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Response Biomedical Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 148 | Aktienzusammenlegung vollzogen | Laie123 | DaxiDowi | 07.02.13 08:40 | ||
2 | 10 | Response Biomedical- Wiedergeburt in 2011 | doschauher | doschauher | 28.01.11 18:16 | |
| 9 | 1.008 | Response Biomedical - Zukunftswert | fuerza_hercuela | Benull | 18.06.10 00:04 | |
| 6 | auf neue höhen | ARTNER514 | Benull | 08.01.10 13:37 | ||
| 4 | mind. 100% schanze | micha1 | hausl | 25.10.09 21:56 |
